The pipeline includes bitopertin for erythropoietic porphyrias and diamond-blackfan anemia; DISC-0974 for anemia of myelofibrosis and chronic kidney disease; and DISC-3405 for polycythemia vera and other hematologic disorders. Disc ended 2025 with approximately $791 million in cash and marketable securities and expects runway into 2029, providing substantial capital for development while the company navigates recent regulatory setbacks.
Cyborg Score Rationale
Disc received an FDA Complete Response Letter on bitopertin in February 2026 and announced a 20% workforce reduction, signaling execution challenges. However, strong cash position and focused pipeline with multiple programs in development support medium-term potential despite near-term regulatory headwinds.
Top Insights
Disc received an FDA Complete Response Letter for bitopertin NDA in February 2026 requiring Phase 3 APOLLO trial data before traditional approval consideration.
Stock rose 12.28% following FDA breakthrough therapy designation despite subsequent CRL, indicating investor confidence in longer-term pipeline.
DISC-0974 reported positive initial Phase 2 data in anemia of myelofibrosis with robust and broad hematologic activity.
20% workforce reduction targeting commercial functions and supporting roles following FDA setback, balancing cash preservation with pipeline advancement.
Named Competitors
EPP Treatment Development — Traditional and emerging therapies for erythropoietic protoporphyria
Myelofibrosis Anemia Treatments — Competing approaches to anemia in myelofibrosis patients
Recent Developments
(February 2026) FDA issues Complete Response Letter for bitopertin, requesting Phase 3 APOLLO data
(February 2026) Company announces 20% workforce reduction and restructuring plan in response to regulatory setback
(January 2026) Company outlines 2026 strategic priorities including FDA approval decision, bitopertin launch preparation, and DISC-0974 Phase 2 updates
(December 2025) Positive initial Phase 2 DISC-0974 data presented at ASH Annual Meeting
Open the full interactive Disc Medicine, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.